Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 967-972

  Desai, Ditina ^a   Goldbach Mansky, Raphaela ^b   Milner, Joshua D ^c   Rabin, Ronald L ^d   Hull, Keith ^b   Pucino, Frank ^e   Colburn, Nona ^b  

^a XLHealth Corporation   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Adverse drug reactions; Anakinra; Anaphylactic reaction; Antirheumatic drugs; Biological therapy; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; DIPHENHYDRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLYCEROL; HISTAMINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN E; INFLIXIMAB; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; ANAMNESIS; ANAPHYLAXIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE REACTION; PRICK TEST; PRIORITY JOURNAL; PRURITUS; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; URTICARIA;

ANAPHYLAXIS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MIDDLE AGED;

EID: 65749112758     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L573     Document Type: Article

References (45)

1. Pucino F Jr., Harbus PT, Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: where are we going? Am J Health Syst Pharm 2006; 63(suppl 4):S19-41.
2. Anton J, Ros J, Ricart S, et al. Desensitization to anakinra in a systemic onset juvenile idiopathic arthritis patient (abstract P-079). Clin Exp Rheumatol 2005;23 (suppl 37):24.
3. Vila AT, Puig L, Fernandez-Figueras MT, Laiz AM, Vidal D, Alomar A. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. Br J Dermatol 2005; 153:417-423 (Pubitemid 41228444)
4. Prescribing information. Remicade (infliximab). Malvern, PA: Centocor, Inc. December 2008. www.remicade.com/remicade/assets/HCP-PPI.pdf (accessed 2009 Mar 6).
5. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-1324
6. Domm A. A patient's reaction to infliximab. Ann Allergy Asthma Immunol 2003;90:298-301. (Pubitemid 36363086)
7. O'Connor M, Buchman A, Marshall G. Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease. Dig Dis Sci 2002;47:1323-1325 (Pubitemid 34606636)
8. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259
9. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486
10. Prescribing information. Enbrel (etanercept). Thousand Oaks, CA: Amgen, December 2006. www.enbrel.com/pdf/enbrel-pi.pdf (accessed 2009 Mar 6).
11. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha- induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61. (Pubitemid 41510416)
12. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579-580 (Pubitemid 34178442)
13. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus erythematosus and TNF-alpha blockers (letter). Lancet 2002;360:646.
14. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis (letter). Ann Intern Med 1999;131:634. (Pubitemid 29494103)
15. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003; 9:176-178 (Pubitemid 36592448)
16. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-1032 (Pubitemid 35221697)
17. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-2390
18. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041-2044 (Pubitemid 30670501)
19. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factoralpha therapy-induced vasculitis: case series. J Rheumatol 2003;30: 2287-2291
20. Roux CH, Brocq O, Albert CBV, Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 2004;71:444-445 (Pubitemid 39335685)
21. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31:1955-1958.
22. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002;41:116-117 (Pubitemid 34537935)
23. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005;61:329-336 (Pubitemid 40637837)
24. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004;3:315-318
25. Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 2003;30:2506-2507 (Pubitemid 37413916)
26. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004;15:280-294 (Pubitemid 39423287)
27. Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum 2006;36:88-98. (Pubitemid 44470788)
28. Kemp SF. Office approach to anaphylaxis: sooner better than later. Am J Med 2007;120:664-668 (Pubitemid 47176509)
29. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
30. Prescribing information. Kineret (anakinra). Thousand Oaks, CA: Amgen, 2001. www.kineretrx.com/professional/pdf/Kineret%20PI%20040423.pdf (accessed 2009 Mar 6).
31. Prescribing information. Humira (adalimumab). North Chicago, IL: Abbott Laboratories, December 2008. www.rxabbott.com/pdf/humira.pdf (accessed 2009 Mar 6).
32. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4:637-641
33. George SJ, Anderson HL, Hsu S. Adalimumab-induced urticaria. Dermatol Online J 2006;12:4. (Pubitemid 46165547)
34. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007;26: 787-788 (Pubitemid 46554095)
35. Sanchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, Ruiz- Villaverde R. Urticaria and angioedema in a patient with Behcet's disease treated with adalimumab (abstract). Clin Exp Rheumatol 2006; 24(suppl 42):S128.
36. Asero R. Multiple drug allergy syndrome: a distinct clinical entity. Curr Allergy Rep 2001;1:18-22.
37. Middleton E, Adkinson NF, Yunginger Busse WWJW, Bochner BS, Holgate ST, Simons FER. Allergy: principles and practice. 5th ed. St. Louis, MO: Mosby, 2003: 1684.
38. Asero R, Tedeschi A, Lorini M, Caldironi G, Barocci F. Sera from patients with multiple drug allergy syndrome contain circulating histaminereleasing factors. Int Arch Allergy Immunol 2003;131:195-200. (Pubitemid 36921058)
39. Pham NH, Baldo BA, Puy RM. Studies on the mechanism of multiple drug allergies. Structural basis of drug recognition. J Immunoassay Immunochem 2001;22:47-73.
40. Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006;55: 27-33.
41. Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 2007;12:125-131 (Pubitemid 46176662)
42. Yamamura M. [Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis - efficacy evaluation, adverse effect detection, and prediction of clinical response]. Nippon Rinsho 2007;65:1269-1275
43. Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 2007;8:761-773 (Pubitemid 47288976)
44. Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 2005;6:481-490 (Pubitemid 41057386)
45. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109-1117